Company: MDCXW
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001062993-25-006485
Chunk: 291

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 291
---
 Fees and Services.

Information relating to this item will be included in the proxy statement for our 2025 Annual Meeting of Shareholders and is hereby incorporated by reference in this Annual Report on Form 10-K, unless the Proxy Statement is not filed prior to 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in which case the information relating to this item will be filed by amendment to this Annual Report on Form 10-K.

PART IV

Item 15.   Exhibits, Financial Statement Schedules

(a)  The following documents are filed as part of this Form 10-K:

(1) Financial Statements:

                    Page

                    Report of Independent Registered Public Accounting Firm (PCAOB ID #274)
                    F-2

                    Report of Independent Registered Public Accounting Firm (PCAOB ID #1930)
                    F-3

                    Consolidated Financial Statements
                    F-4

                    Consolidated Balance Sheets
                    F-5

                    Consolidated Statements of Operations and Comprehensive Loss
                    F-6

                    Consolidated Statements of Changes in Shareholders' Equity
                    F-7

                    Consolidated Statements of Cash Flows
                    F-8

(2) Financial Statement Schedules:

None.

(3) Exhibits

We hereby file as part of this Report the exhibits listed in the attached Exhibit Index. Exhibits which are incorporated herein by reference can be accessed on the SEC website at www.sec.gov. In addition, we file or furnish periodic reports and amendments thereto, including our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, proxy statements and other information with the SEC. The SEC maintains a website www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically.

                86

                    ExhibitNumber
                     
                    Description

                    2.1#
                     
                    Amended and Restated Business Combination Agreement, dated May 12, 2023, by and among the Registrant, RBx Capital LP, SkinJect, Inc. and the Shareholders of SkinJect, Inc. (incorporated by reference from Exhibit 2.1 to the Registrant's Registration Statement on Form F-1, filed with the SEC on May 29, 2024)

                    2.2
                     
                    Amendment No. 1 to Amended and